Line 3: |
Line 3: |
| | | |
| ==Description== | | ==Description== |
| + | One of the most common causes of an acquired coagulopathy |
| + | in dogs is the accidental ingestion of an anticoagulant |
| + | rodenticide. The first generatlion |
| + | coumarin-derivative anticoagulant, |
| + | warfarin. has a short half-life |
| + | of about 12 hours and a relatively |
| + | low toxicity in non-target species. |
| + | Therefore, repeated or massive exposure |
| + | would generally be required to |
| + | produce clinical bleeding in a dog. |
| + | The second generation coumarin |
| + | derivatives (bromadiolone and brodifacoum) |
| + | and indandione rodenticides |
| + | (pindone and diaphacinone), developed |
| + | in response to wartarin resistance |
| + | in target species, are tar more |
| + | potent than warfarin. They have much |
| + | longer lasting etfects (half-lives of |
| + | four to six days) as they are more |
| + | completely bound to plasmla proteins |
| + | and, compared to warfarin, have an |
| + | enhanced tendency to accumulate in |
| + | hepatic tissue. Secondary poisoning |
| + | through ingestion ol killed target |
| + | species is more likely to occur with |
| + | these latter agents. |
| + | The coumarin derivatives exert interaction of |
| + | their anticoagulant eftect by inhibiting the enzyme, vitamin K epoxide reductase (see box on page 63). This enizymiie is a component of |
| + | the vitamin K epoxide cycle required tf)r hepatic synthesis |
| + | of the functional clotting factors F-II, F-VII, F-IX and |
| + | F-X. Inhibition of the enzyme causes the accumulation of the inactive vitamin K epoxide and prevents the carboxylation |
| + | of vitamin K-dependent coagulation proteins. The |
| + | acarboxy precursor proteins are incapable of being activated |
| + | during the coagulation process and thus cannot |
| + | actively participate in fibrin formation. |
| | | |
| ==Signalment== | | ==Signalment== |